Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125485331 | 12548533 | 1 | I | 20160627 | 20160706 | 20160712 | 20160712 | EXP | GB-DEXPHARM-20161491 | DEXCEL | 85.00 | YR | E | F | Y | 71.00000 | KG | 20160712 | OT | GB | GB |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125485331 | 12548533 | 1 | PS | OMEPRAZOLE. | OMEPRAZOLE | 1 | Oral | Y | U | 0 | 20 | MG | |||||||
| 125485331 | 12548533 | 2 | C | ALENDRONIC ACID | ALENDRONIC ACID | 1 | 0 | ||||||||||||
| 125485331 | 12548533 | 3 | C | Calcichew D3 | CALCIUMCHOLECALCIFEROL | 1 | 0 | ||||||||||||
| 125485331 | 12548533 | 4 | C | GLICLAZIDE | GLICLAZIDE | 1 | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 125485331 | 12548533 | 1 | Dyspepsia |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 125485331 | 12548533 | HO |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 125485331 | 12548533 | Hypocalcaemia | |
| 125485331 | 12548533 | Hypomagnesaemia |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 125485331 | 12548533 | 1 | 2007 | 20160627 | 0 |